Latest Period
Q1 2026
Security Snapshot
Dyne Therapeutics, Inc. - Common Stock (DYN) Institutional Ownership
CUSIP: 26818M108
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
227
Shares (Excl. Options)
187,846,236
Price
$18.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- DYN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 187,846,236
- Total 13F value
- $3,402,448,596
- Portfolio coverage rank
- 0.01%
- Share change
- +9,476,431
- Value change
- +$164,547,456
- Number of holders
- 227
- Shares outstanding
- 164,426,217
- SEC-reported price per share
- $18.46
- Insider filing price
- $18.46
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DYN - Dyne Therapeutics, Inc. - Common Stock is tracked under CUSIP 26818M108.
- 227 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 231 to 227 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,479,399,314 to $3,402,448,596.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 227 institutions filings for Q1 2026.
Security key
26818M108
Latest holder period
Q1 2026
13F holders
227
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
DYN full holder history
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Dyne Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 26818M108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
DYN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19% | +16% | $557,222,998 | +$76,153,288 | 30,785,801 | +16% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 8.3% | -2.2% | $247,017,506 | -$4,350,263 | 13,647,376 | -1.7% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| FMR LLC | 5.4% | +16% | $161,252,536 | +$67,217,717 | 8,908,980 | +71% | FMR LLC | 31 Mar 2026 |
| BlackRock, Inc. | 5.8% | $73,080,236 | 6,577,879 | BlackRock, Inc. | 31 Mar 2025 | |||
| Atlas Venture Fund XI, L.P. | 4% | $72,275,396 | 5,713,470 | Atlas Venture Associates XI, L.P. | 30 Sep 2025 | |||
| Forbion Capital Fund IV Cooperatief U.A. | 4.8% | $60,000,055 | 5,400,545 | ForDyne B.V. | 31 Mar 2025 | |||
| RTW INVESTMENTS, LP | 1.5% | -72% | $18,782,199 | -$39,196,902 | 1,690,567 | -68% | RTW Investments, LP | 31 Mar 2025 |
| Point72 Asset Management, L.P. | 1.5% | -72% | $18,546,390 | -$39,187,803 | 1,669,342 | -68% | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 31 Mar 2026, 227 institutional investors reported holding 187,846,236 shares of Dyne Therapeutics, Inc. - Common Stock (DYN). This represents 114% of the company’s total 164,426,217 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
89%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19% | 30,785,801 | +76% | 0.38% | $558,147,000 |
| JANUS HENDERSON GROUP PLC | 8.3% | 13,647,376 | -1.7% | 0.12% | $247,426,927 |
| BlackRock, Inc. | 7.1% | 11,699,870 | +4.5% | 0% | $212,118,644 |
| Atlas Venture Life Science Advisors, LLC | 5.6% | 9,130,465 | 0% | 21% | $165,535,330 |
| FMR LLC | 5.4% | 8,908,980 | +36% | 0.01% | $161,519,805 |
| Orbis Allan Gray Ltd | 4.1% | 6,762,231 | +41% | 0.52% | $122,599,248 |
| STATE STREET CORP | 4% | 6,653,746 | -0.58% | 0% | $120,632,415 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 6,405,069 | 0% | 0% | $116,123,901 |
| PERCEPTIVE ADVISORS LLC | 2.8% | 4,668,839 | +34% | 1.7% | $84,646,051 |
| FCPM III SERVICES B.V. | 2.8% | 4,644,386 | -15% | 12% | $84,202,718 |
| TCG Crossover Management, LLC | 2.8% | 4,615,144 | 0% | 2.4% | $83,672,561 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.5% | 4,162,041 | 0% | 0% | $75,457,803 |
| Vestal Point Capital, LP | 2.4% | 4,000,000 | +3233% | 2% | $72,520,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 3,504,114 | +7.4% | 0% | $63,542,557 |
| JPMORGAN CHASE & CO | 2% | 3,253,473 | -8.4% | 0% | $55,601,855 |
| ARMISTICE CAPITAL, LLC | 1.9% | 3,175,110 | -2.3% | 1.9% | $57,564,744 |
| Frazier Life Sciences Management, L.P. | 1.9% | 3,153,082 | 0% | 1.5% | $57,165,377 |
| ORBIMED ADVISORS LLC | 1.8% | 2,917,884 | +32% | 1.2% | $52,901,237 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 2,328,373 | +0.2% | 0% | $42,215,000 |
| Siren, L.L.C. | 1.4% | 2,229,125 | -36% | 1.1% | $40,414,036 |
| Venrock Adviser, LLC | 1.3% | 2,173,913 | 0% | 1.5% | $39,413,043 |
| FRANKLIN RESOURCES INC | 1.2% | 2,009,082 | +0.12% | 0.01% | $36,424,648 |
| Deep Track Capital, LP | 1.2% | 2,000,000 | -25% | 0.75% | $36,260,000 |
| SAMLYN CAPITAL, LLC | 1.2% | 1,922,543 | +29% | 0.6% | $34,855,705 |
| GOLDMAN SACHS GROUP INC | 1% | 1,723,116 | -25% | 0% | $31,240,093 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 187,846,236 | $3,402,448,596 | +$164,547,456 | $18.13 | 227 |
| 2025 Q4 | 177,889,364 | $3,479,399,314 | +$511,413,774 | $19.56 | 231 |
| 2025 Q3 | 155,774,921 | $1,970,440,035 | +$381,733,004 | $12.65 | 205 |
| 2025 Q2 | 128,553,808 | $1,223,875,095 | +$58,226,785 | $9.52 | 195 |
| 2025 Q1 | 121,788,688 | $1,284,331,056 | -$75,923,327 | $10.46 | 202 |
| 2024 Q4 | 111,635,776 | $2,630,327,572 | -$39,471,758 | $23.56 | 199 |
| 2024 Q3 | 112,428,939 | $4,033,469,001 | -$6,349 | $35.92 | 200 |
| 2024 Q2 | 110,972,098 | $3,915,861,443 | +$555,159,053 | $35.29 | 191 |
| 2024 Q1 | 95,365,001 | $2,707,385,907 | +$786,881,972 | $28.39 | 167 |
| 2023 Q4 | 69,922,072 | $929,957,219 | +$57,596,260 | $13.30 | 123 |
| 2023 Q3 | 59,888,832 | $536,594,556 | +$1,685,315 | $8.96 | 114 |
| 2023 Q2 | 59,189,838 | $665,851,766 | +$50,911,029 | $11.25 | 117 |
| 2023 Q1 | 54,627,733 | $628,721,822 | +$56,536,368 | $11.52 | 125 |
| 2022 Q4 | 49,732,095 | $576,377,450 | +$50,130,248 | $11.59 | 112 |
| 2022 Q3 | 44,533,854 | $565,571,380 | -$9,010,573 | $12.70 | 100 |
| 2022 Q2 | 46,679,856 | $320,706,640 | -$8,056,035 | $6.87 | 87 |
| 2022 Q1 | 47,256,134 | $455,432,690 | -$4,233,139 | $9.64 | 90 |
| 2021 Q4 | 47,794,946 | $568,260,037 | +$18,929,604 | $11.89 | 90 |
| 2021 Q3 | 32,306,202 | $524,727,164 | -$16,367,213 | $16.24 | 80 |
| 2021 Q2 | 35,805,078 | $753,366,735 | +$36,093,361 | $21.04 | 75 |
| 2021 Q1 | 31,379,394 | $487,292,000 | +$72,426,450 | $15.53 | 72 |
| 2020 Q4 | 26,339,155 | $552,433,805 | +$28,795,524 | $21.00 | 67 |
| 2020 Q3 | 24,527,914 | $493,744,000 | +$493,744,015 | $20.19 | 49 |